While lower-rely MBL not often progresses to CLL, large-rely MBL progresses to CLL demanding therapy at a price of one% to two% each year. Higher-count MBL is distinguished from Rai 0 CLL dependant on whether the B-mobile rely is above or under five × 109/L. Even though individuals with both equally substantial-rely MBL and CLL Rai phase 0 are at